Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis

被引:95
作者
Wongjarupong, Nicha [1 ,2 ,3 ]
Assavapongpaiboon, Buravej [1 ,2 ,4 ]
Susantitaphong, Paweena [2 ,5 ]
Cheungpasitporn, Wisit [6 ]
Treeprasertsuk, Sombat [1 ,2 ]
Rerknimitr, Rungsun [1 ,2 ]
Chaiteerakij, Roongruedee [1 ,2 ]
机构
[1] Chulalongkorn Univ, Fac Med, Div Gastroenterol, Dept Med, 1873 Rama 4 Rd, Bangkok 10330, Thailand
[2] King Chulalongkorn Mem Hosp, 1873 Rama 4 Rd, Bangkok 10330, Thailand
[3] Chulalongkorn Univ, Dept Physiol, Fac Med, Bangkok, Thailand
[4] Chulalongkorn Univ, Fac Med, Dept Parasitol, Bangkok, Thailand
[5] Chulalongkorn Univ, Div Nephrol, Dept Med, Fac Med, Bangkok, Thailand
[6] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA
关键词
Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; NAFLD; NASH; Cholangiocarcinoma; Bile duct cancer; Risk factor; INTRAHEPATIC CHOLANGIOCARCINOMA; UNITED-STATES; STEATOHEPATITIS; ASSOCIATION; EPIDEMIOLOGY; RELEVANCE;
D O I
10.1186/s12876-017-0696-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) has been recently identified as a risk factor of gastrointestinal tract cancers, especially hepatocellular carcinoma, and colorectal cancer. Whether NAFLD is a risk factor for cholangiocarcinoma (CCA) remains inconclusive. The aim of this study is to determine a potential association between NAFLD and CCA, stratifying by its subtypes; intrahepatic CCA (iCCA), and extrahepatic CCA (eCCA). Methods: A search was conducted for relevant studies published up to April 2017 using MEDLINE, EMBASE, Scopus and Cochrane databases. Odds ratio (OR) and adjusted OR with 95% confidence interval (CI) were estimated using a random-effects model. Subgroup analyses were conducted with study characteristics. Results: Seven case-control studies were included in the analysis, with a total of 9,102 CCA patients (5,067 iCCA and 4,035 eCCA) and 129,111 controls. Overall, NAFLD was associated with an increased risk for CCA, with pooled OR of 1.95 (95%CI: 1.36-2.79, I-2=76%). When classified by subtypes, NAFLD was associated with both iCCA and eCCA, with ORs of 2.22 (95%CI: 1.52-3.24, I-2=67%) and 1.55 (95%CI: 1.03-2.33, I-2=69%), respectively. The overall pooled adjusted ORs were 1.97 (95%CI: 1.41-2.75, I-2=71%), 2.09 (95%CI, 1.49-2.91, I-2=42%) and 2.05 (95%CI, 1.59-2.64, I-2=0%) for all CCAs, iCCA, and eCCA, respectively. Conclusions: This meta-analysis suggests that NAFLD may potentially increase the risk of CCA development. The magnitude of NAFLD on CCA risk is greater for iCCA than eCCA subtype, suggestive of a common pathogenesis of iCCA and hepatocellular carcinoma. Further studies to confirm this association are warranted.
引用
收藏
页数:8
相关论文
共 29 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]  
[Anonymous], The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta- Analysis
[3]   Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) [J].
Banales, Jesus M. ;
Cardinale, Vincenzo ;
Carpino, Guido ;
Marzioni, Marco ;
Andersen, JesperB. ;
Invernizzi, Pietro ;
Lind, Guro E. ;
Folseraas, Trine ;
Forbes, Stuart J. ;
Fouassier, Laura ;
Geier, Andreas ;
Calvisi, Diego F. ;
Mertens, Joachim C. ;
Trauner, Michael ;
Benedetti, Antonio ;
Maroni, Luca ;
Vaquero, Javier ;
Macias, Rocio I. R. ;
Raggi, Chiara ;
Perugorria, Maria J. ;
Gaudio, Eugenio ;
Boberg, Kirsten M. ;
Marin, Jose J. G. ;
Alvaro, Domenico .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2016, 13 (05) :261-280
[4]   Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: Implications for treatment [J].
Carter-Kent, Christine ;
Zein, Nizar N. ;
Feldstein, Ariel E. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (04) :1036-1042
[5]   Risk Factors for Intrahepatic Cholangiocarcinoma: Association Between Metformin Use and Reduced Cancer Risk [J].
Chaiteerakij, Roongruedee ;
Yang, Ju Dong ;
Harmsen, William S. ;
Slettedahl, Seth W. ;
Mettler, Teresa A. ;
Fredericksen, Zachary S. ;
Kim, W. Ray ;
Gores, Gregory J. ;
Roberts, Rosebud O. ;
Olson, Janet E. ;
Therneau, Terry M. ;
Roberts, Lewis R. .
HEPATOLOGY, 2013, 57 (02) :648-655
[6]   Medical Risk Factors Associated with Cholangiocarcinoma in Taiwan: A Population-Based Case-Control Study [J].
Chang, Jeffrey S. ;
Tsai, Chia-Rung ;
Chen, Li-Tzong .
PLOS ONE, 2013, 8 (07)
[7]   Aspirin use and the risk of cholangiocarcinoma [J].
Choi, Jonggi ;
Ghoz, Hassan M. ;
Peeraphatdit, Thoetchai ;
Baichoo, Esha ;
Addissie, Benyam D. ;
Harmsen, William S. ;
Therneau, Terry M. ;
Olson, Janet E. ;
Chaiteerakij, Roongruedee ;
Roberts, Lewis R. .
HEPATOLOGY, 2016, 64 (03) :785-796
[8]   Prevalence and Relevance of Nonalcoholic Fatty Liver Disease in Patients with Primary Sclerosing Cholangitis [J].
Doycheva, Iliana ;
Cox, Kristen ;
Haseeb, Abdul ;
Adler, Douglas G. .
DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (07) :1645-1646
[9]  
Eng G, 2016, LAB INVEST, V96, p419A
[10]   Cell Lineage Tracing Reveals a Biliary Origin of Intrahepatic Cholangiocarcinoma [J].
Guest, Rachel V. ;
Boulter, Luke ;
Kendall, Timothy J. ;
Minnis-Lyons, Sarah E. ;
Walker, Robert ;
Wigmore, Stephen J. ;
Sansom, Owen J. ;
Forbes, Stuart J. .
CANCER RESEARCH, 2014, 74 (04) :1005-1010